Categories AlphaGraphs, Earnings, Health Care
ANGO Earnings: AngioDynamics swings to profit in Q4; revenues beat estimates
AngioDynamics Inc. (NASDAQ: ANGO) on Tuesday reported a modest profit for the fourth quarter of 2022 compared to breakeven last year. Revenues increased in double-digits and topped expectations.
The medical device maker reported adjusted earnings of one cent during the three-month period, marking an improvement from the prior-year quarter when the bottom line was breakeven. The latest number came in line with the consensus estimates.
Revenues increased 13% year-over-year to $86.9 million in the May quarter and topped analysts’ forecast. The top line benefitted from strong performance by all three operating segments.
Check this space to read management/analysts’ comments on AngioDynamics’ Q4 2022 earnings
“We delivered on the strategic objectives for the fiscal year 2022 that we laid out a year ago during our Investor and Technology Day while managing through a number of macro-related headwinds, including supply chain disruptions and ongoing inflationary pressures. During our fourth quarter, we reduced our backlog as our manufacturing capacity improved, exiting the quarter more than 40% above the lows we experienced in December,” said AngioDynamics’ CEO Jim Clemmer.
Most Popular
WMT Earnings: All you need to know about Walmart’s Q2 2023 earnings results
Walmart Inc. (NYSE: WMT) reported second quarter 2023 earnings results today. Total revenue increased 8.4% year-over-year to $152.9 billion. Revenues grew 9.1% in constant currency. Consolidated net income attributable to
Rivian (RIVN) reaffirms production goals. Will it be a smooth ride?
The evolution of the electric vehicle industry accelerated in recent years even as innovations in battery technology and affordability brought EVs into the mainstream. Encouraged by the success of market
Pfizer (PFE): A look at the headwinds and tailwinds this pharma giant faces in the near term
Shares of Pfizer Inc. (NYSE: PFE) were down on Monday. The stock has dropped 15% year-to-date and there is a mixed sentiment surrounding the company’s growth prospects. Pfizer has benefited
